医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Key Charpentier/Doudna CRISPR Patent Upheld by China National Intellectual Property Administration

2024年03月26日 PM07:38
このエントリーをはてなブックマークに追加


 

DUBLIN

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced its patent CN201380038920.6 was upheld by the China National Intellectual Property Administration (CNIPA) in response to an invalidation challenge.

The patent was filed by Dr. Charpentier, together with The Regents of the University of California and University of Vienna (collectively known as CVC), for “Methods and Compositions for RNA-guided Target DNA Modification and for RNA-guided Transcription Regulation”. The decision to uphold the patent right in China follows a recent decision by the Japanese Patent Office earlier this year to uphold JP6692856, also part of the CVC portfolio1.

During the proceedings, novelty and inventive step were contested. In the decision, the CNIPA rejected both challenges to patentability, including maintaining that the priority application enabled uses of CRISPR/Cas9 in eukaryotic cells. The decision by the CNIPA, fully upholding the patent, further demonstrates its validity and value as part of the patent collection for use of the CRISPR/Cas9 technology.

Michael Arciero, Vice-President of Intellectual Property and Commercial Development, ERS Genomics, said: “The decision by the CNIPA is testament to the strength of the foundational CVC CRISPR/Cas9 patent portfolio. Alongside the recent decision in Japan this demonstrates a global trend, and reinforces the importance of research organisations having the correct intellectual property rights in place when working with this technology.”

ERS Genomics provides licensing to CRISPR/Cas9 technology for companies interested in pursuing its use in their commercial programs. With 89 patents held in over 90 countries, ERS Genomics licenses these patents via its direct license from Emmanuelle Charpentier and now has nearly 150 licenses in place worldwide.

  1. https://ersgenomics.com/key-charpentier-doudna-crispr-patent-upheld-by-japanese-patent-office/

For a high resolution image please contact Zyme Communications

View source version on businesswire.com: https://www.businesswire.com/news/home/20240326545204/en/

CONTACT

Dr Ben Rutter

Zyme Communications

Tel: +44(0)7920 770 935

Email: ben.rutter@zymecommunications.com

同じカテゴリーの記事 

  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表
  • The Office of Health Economics: Adult Vaccination Programmes Deliver Socio-economic Benefits up to 19 Times Initial Investment, According to New Report
  • Masimo创始人兼首席执行官Joe Kiani将在智利举行的全球患者安全峰会上谈论人工智能
  • マシモ創業者兼最高経営責任者(CEO)のジョー・キアニがチリで開催される世界患者安全サミットでAIについて講演
  • Codone Biotech to Present Data on its Suppressor-tRNA Platform in Disease Models with Nonsense Mutations (Premature Termination Codons)